Open AccessS900 Real World Treatment (Tx) Patterns and Healthcare Costs Among U.S. Commercially Insured Adults Initiating Biologics for Ulcerative Colitis (UC)
Author(s) -
Douglas C. Wolf,
Justin Puckett,
Juliana Setyawan,
Christopher J. Rabbat,
Sheldon Sloan,
Sachin KamalBahl
Publication year - 2021
Publication title -
the american journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.907
H-Index - 252
eISSN - 1572-0241
pISSN - 0002-9270
DOI - 10.14309/01.ajg.0000777132.27251.cf
Subject(s) - medicine , vedolizumab , discontinuation , golimumab , infliximab , adalimumab , real world data , ulcerative colitis , retrospective cohort study , health care , disease , economics , economic growth , data science , computer science